Novel modified peptide compound derived from transcription factor cp2c complex formation-regulating peptide (ACP52), exhibiting cancer therapeutic activity
Novel peptoid compounds with high stability and permeability address the limitations of peptide-based cancer treatments by inhibiting the CP2c complex, enhancing cancer treatment efficacy and offering oral administration possibilities.
WO2026155427A1PCT designated stage Publication Date: 2026-07-23KIM CHUL GEUN
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- KIM CHUL GEUN
- Filing Date
- 2025-12-26
- Publication Date
- 2026-07-23
AI Technical Summary
Technical Problem
Existing peptide-based cancer treatments face issues such as degradation by proteolytic enzymes, low cell permeability, and side effects due to damage to normal cells, necessitating parenteral administration and limiting their effectiveness.
Method used
Development of novel peptoid compounds with high in vivo stability and cell permeability that inhibit the formation of the transcription factor CP2c complex, allowing for effective cancer treatment without the need for cell-penetrating peptides.
Benefits of technology
The peptoid compounds exhibit enhanced stability and permeability, inhibiting cancer cell growth and proliferation, including synergistic effects with existing anticancer drugs, and provide a potential for oral administration.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure KR2025022843_23072026_PF_FP_ABST
Abstract
The present invention relates to a novel modified peptide compound. The compound of the present invention is stable in vivo, has high cell permeability, and exhibits an effect of inhibiting cancer cells in various carcinomas, and thus can be effectively used for preventing or treating cancer.
Need to check novelty before this filing date? Find Prior Art